The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis
(IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
In patients with neuromuscular disorders such as inclusion body myositis
, persistent cTnT and CK-MB increases without cTnl increases have been reported (2, 3).
This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis
(IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The patient expired approximately two weeks after his diagnosis of inclusion body myositis
Skin exam usually is normal in patients with inclusion body myositis
Inclusion body myositis
in a patient with long standing rheumatoid arthritis treated with anti-TNF [alpha] and rituximab.
The researchers say that beyond muscular dystrophy, their finding shows that muscle tissue can be an effective avenue to deliver therapeutic genes for a variety of muscle disorders, including some that are resistant to treatment, such as inclusion body myositis
, and in conditions where muscle is atrophied, such as in cancer and aging.
1) Other reasons for non-response include alternative diagnoses, such as inclusion body myositis
, or an underlying malignancy.
BOSTON -- Failure to respond to standard immunosuppressant therapy may be the first sign that a patient's apparent polymyositis actually is inclusion body myositis
, according to Dr.
Janet Brown of New Marske organised the jam-packed day to raise awareness after one of her relatives was diagnosed with Inclusion Body Myositis
Diseases affecting muscles include polymyositis, dermatomyositis and inclusion body myositis
They are contrasted with other types of inflammatory myopathies, including inclusion body myositis
and myositis caused by infection or drug reactions.
USPRwire, Mon May 04 2015] Global Markets Direct's, 'Inclusion Body Myositis
(IBM) - Pipeline Review, H1 2015', provides an overview of the Inclusion Body Myositis
(IBM)'s therapeutic pipeline.
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis